Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IRHYTHM TECHNOLOGIES, INC.

(IRTC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IRhythm Technologies : Says Study Shows Monitoring Atrial Fibrillation with Zio Device Reduces Heart Risk

10/06/2021 | 02:18pm EST


ę MT Newswires 2021
All news about IRHYTHM TECHNOLOGIES, INC.
11/08Morgan Stanley Adjusts Price Target on iRhythm Technologies to $114 From $77, Maintains..
MT
11/05IRHYTHM TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/04IRhythm Technologies Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04IRhythm Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021
CI
11/04Earnings Flash (IRTC) IRHYTHM Posts Q3 Revenue $85.4M, vs. Street Est of $83.6M
MT
11/04Earnings Flash (IRTC) IRHYTHM Posts Q3 Loss $-0.81, vs. Street Est of $-1.08
MT
11/04IRHYTHM TECHNOLOGIES, INC. : Results of Operations and Financial Condition, Amendment or W..
AQ
11/04IRhythm Technologies Announces Third Quarter 2021 Financial Results
AQ
11/04IRhythm Technologies, Inc. Revises Revenue Guidance for the Year of 2021
CI
11/04IRhythm Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
More news
Analyst Recommendations on IRHYTHM TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 319 M - -
Net income 2021 -105 M - -
Net cash 2021 49,5 M - -
P/E ratio 2021 -27,3x
Yield 2021 -
Capitalization 2 884 M 2 884 M -
EV / Sales 2021 8,88x
EV / Sales 2022 7,93x
Nbr of Employees 1 157
Free-Float 98,3%
Chart IRHYTHM TECHNOLOGIES, INC.
Duration : Period :
iRhythm Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRHYTHM TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 98,00 $
Average target price 114,80 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Quentin S. Blackford President, Chief Executive Officer & Director
Douglas J. Devine Chief Financial Officer
Abhijit Y. Talwalkar Chairman
Judith Lenane Chief Clinical Officer & Executive VP-Products
Mark J. Day Executive Vice President-Research & Development
Sector and Competitors